FIL_MIRO: "MIRO" Molecularly Oriented Immuno-radio-therapy

Sponsor

Fondazione Italiana Linfomi ONLUS (Other)

Overall Status

Completed

CT.gov ID

NCT02710643

Collaborator

(none)

110

Enrollment

Locations

Arms

90.2

Duration (Months)

4.1

Patients Per Site

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Phase II prospective multicenter study for stage I/II Follicular Lymphoma treated with involved-field radiotherapy (IFRT) at doses of 24 Gy) with or without Ofatumumab for 8 weekly doses on molecular basis. Patients with positive basal Bcl-2 will be followed every 3 months and with Bcl-2 detection every 6 months for 3 years. Patient with negative basal Bcl-2 will be followed every 3 months without further Bcl-2 detection.

Ofatumumab treatment will be administered to:

Patients with positive basal PCR for Bcl-2-IgH rearrangement in BM and/or PB, resulting still positive after IFRT;
Patients with positive basal PCR for Bcl-2-IgH in

Condition or Disease	Intervention/Treatment	Phase
Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma Grade 3A	Drug: OFATUMUMAB	Phase 2

Detailed Description

Stage I/IIA follicular lymphoma (FL) is considered a localized disease that can be adequately treated with radiotherapy alone. This strategy is recommended by the guidelines of the "Società Italiana di Ematologia" (SIE) and of the "European Society for Medical Oncology" (ESMO) The accurate definition of the truly localised forms represents a crucial issue in order to ensure an appropriate treatment design for such patients. The characteristic t(14;18) translocation, which leads to the over-expression of the Bcl-2 gene, is found in approximately 85% of FL; cells bearing this translocation can be detected in the peripheral blood (PB) or bone marrow (BM) by polymerase chain reaction (PCR).

PCR for the t(14;18) translocation provides a sensitive device to identify the presence of minimal non-Hodgkin lymphoma (NHL) cell contamination. Previous experiences have demonstrated that despite the limited stage, Bcl-2/IgH+ cells can be found at diagnosis in PB and/or BM of the majority of the patients. After treatment with local radiotherapy confined to the involved lymph node(s) only, disappearance of circulating Bcl-2/IgH+ cells in PB and/or BM was demonstrated in approximately 60% of positive patients. Quantitative PCR demonstrated the feasibility of clearing PB and BM Bcl-2+ cells after local irradiation of the primary site of the disease only when the basal number of lymphoma cells was <1:100 000.

Anti-CD20 monoclonal antibody treatment has clearly demonstrated, both alone and in combination with chemotherapy and radiotherapy, a high therapeutic potential in FL. A significant impact of treatment with the anti CD20 monoclonal antibody in reducing the minimal residual disease in FL has been demonstrated in several studies when used as consolidation or during the maintenance phase.

No data are currently available concerning the ability of anti-CD20 antibody treatment in reducing the proportion of Bcl-2 positive residual cells after radiotherapy in localized FL. The objective of this study is to take advantage of the therapeutic potential of anti-CD20 monoclonal antibody to reduce or eliminate minimal residual disease in patients with FL in localized stage (I/II) after conventional treatment with local radiotherapy of the involved site(s). The effectiveness of anti-CD20 monoclonal antibody treatment will be determined by the proportion of negativization of residual Bcl-2 positive cells after radiotherapy, evaluated by qualitative and quantitative PCR detection of viable Bcl-2/IgH rearranged cells in PB and/or BM.

Study Design

Study Type:

Interventional

Actual Enrollment :

110 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

"MIRO" (Molecularly Oriented Immuno - Radio -Therapy): Multicenter Phase II Study for the Treatment of the Molecular Basis of Stage I / II Follicular Lymphoma With Local Radiotherapy With / Without Ofatumumab

Study Start Date :

Oct 1, 2014

Actual Primary Completion Date :

Apr 1, 2018

Actual Study Completion Date :

Apr 7, 2022

Arms and Interventions

Arm	Intervention/Treatment
No Intervention: MRD - BEFORE RT Patients who had negative baseline Bcl-2 in PB and BM will not undergo further treatment after radiotherapy; they will not repeat Bcl-2 during subsequent follow-up visits.
No Intervention: MRD + BEFORE RT AND MRD - AFTER RT Patients who had positive baseline Bcl-2 in PB and / or BM and become negative after local radiotherapy will not undergo further treatment.
Experimental: MRD + BEFORE RT AND MRD + AFTER RT Patients who had positive baseline Bcl-2 in PB and / or BM and remain positive after local radiotherapy get Ofatumumab (8 weekly infusion of 1000 mg total dose). Patients Bcl-2 negativized either after radiotherapy or after Ofatumumab, who became Bcl-2 positive during the follow-up monitoring will be treated/retreated with Ofatumumab 8 weekly infusions at the conventional dose of 1000 mg; Bcl-2 monitoring will be continued subsequently according to the program.In case of persistent positive PCR after Ofatumumab the treatment will not be repeated.	Drug: OFATUMUMAB 8 weekly infusion of 1000 mg total dose Other Names: ARZERRA

Arm

Intervention/Treatment

No Intervention: MRD - BEFORE RT

Patients who had negative baseline Bcl-2 in PB and BM will not undergo further treatment after radiotherapy; they will not repeat Bcl-2 during subsequent follow-up visits.

No Intervention: MRD + BEFORE RT AND MRD - AFTER RT

Patients who had positive baseline Bcl-2 in PB and / or BM and become negative after local radiotherapy will not undergo further treatment.

Experimental: MRD + BEFORE RT AND MRD + AFTER RT

Patients who had positive baseline Bcl-2 in PB and / or BM and remain positive after local radiotherapy get Ofatumumab (8 weekly infusion of 1000 mg total dose). Patients Bcl-2 negativized either after radiotherapy or after Ofatumumab, who became Bcl-2 positive during the follow-up monitoring will be treated/retreated with Ofatumumab 8 weekly infusions at the conventional dose of 1000 mg; Bcl-2 monitoring will be continued subsequently according to the program.In case of persistent positive PCR after Ofatumumab the treatment will not be repeated.

Drug: OFATUMUMAB

8 weekly infusion of 1000 mg total dose

Other Names:

ARZERRA

Outcome Measures

Primary Outcome Measures

Bcl-2 negativization after Ofatumumab [4 YEARS FROM ENROLLMENT]
The proportion of Bcl-2 negativization after Ofatumumab treatment will be estimated by the proportion, and its confidence interval, of residual Bcl-2 positive cases after radiotherapy, which will became negative after Ofatumumab treatment

Secondary Outcome Measures

Clinical response rate [4 YEARS FROM ENROLLMENT]
Clinical response rate will be evaluated by the proportion and its confidence interval of patients achieving overall response (OR) complete response (CR) and partial response (PR).
Overall response [4 YEARS FROM ENROLLMENT]
overall response (OR)
Partial response [4 YEARS FROM ENROLLMENT]
partial response (PR)
Complete response [4 YEARS FROM ENROLLMENT]
complete response (CR)
Progression Free Survival [4 YEARS FROM ENROLLMENT]
Progression Free Survival (PFS) is defined as the length of time between the date of registration and the earliest date of disease progression or death due to any cause; If the patients doesn't not have a documented date of progression or death, the PFS will be censored at the date of last adequate assessment. Relapse Free Survival (RFS) is defined as the length of time between the achievement of Complete Remission (CR) and Relapse of disease
Relapse Free Survival [4 YEARS FROM ENROLLMENT]
Relapse Free Survival (RFS) is defined as the length of time between the achievement of Complete Remission (CR) and Relapse of disease

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Histologically confirmed follicular lymphoma grade I-IIIa;
Stage IA or IIA (no more than 2 contiguous nodal regions) non bulky (<7 cm);
FLIPI ≤2, FLIPI2 ≤2;
Previously untreated;
Age ≥ 18;
Informed consent;
Staging with PET-CT, bone marrow biopsy;
Qualitative/quantitative PCR basal evaluation of Bcl-2/IgH rearranged cells in peripheral blood and bone marrow.

Exclusion Criteria:

Follicular lymphoma grade IIIb;
Stage greater than II with more than 2 nodal sites and/or B symptoms and/or bulky disease (>7 cm);
FLIPI >2, FLIPI2 >2;
Age < 18;
Previous treatments for non-Hodgkin's lymphoma;
Dementia;
Impossibility to subscribe the informed consent;
Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones or stable chronic liver disease per investigator assessment);
Treatment with any known non-marketed drug substance or experimental therapy within 5 terminal half lives or 4 weeks prior to enrollment, whichever is longer, or currently participating in any other interventional clinical study;
Other past or current malignancy. Subjects who have been free of malignancy for at least 5 years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible;
Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active Hepatitis C;
History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae;
Known HIV positive;
Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months prior to start of treatment, congestive heart failure (NYHA III-IV), and arrhythmia unless controlled by therapy, with the exception of extra systoles or minor conduction abnormalities;
Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease which in the opinion of the investigator may represent a risk for the patient;
Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a quantitative HBV-DNA test will be performed and if positive the subject will be excluded. Patients with HBcAb positivity and negative HBV DNA should be prophilactically treated with oral Lamivudine (100 mg /day) in case of treatment with Ofatumumab, to be prosecuted 12 months after treatment;
Positive serology for hepatitis C (HC) defined as a positive test for HCAb, in which case reflexively perform a HCV-RNA on the same sample to confirm the result;
Hematologic and blood chemistry exclusion criteria:
platelets <50 x 109/L;
neutrophils <1.0 x 109/L;
creatinine >2.0 times upper normal limit;
total bilirubin >1.5 times upper normal limit;
ALT >2.5 times upper normal limit;
alkaline phosphatase >2.5 times upper normal limit;
Pregnant or lactating women. Women of childbearing potential must have a negative pregnancy test at screening:
Women of childbearing potential, including women whose last menstrual period was less than one year prior to screening, unable or unwilling to use adequate contraception from study start to one year after the last dose of protocol therapy. Adequate contraception is defined as hormonal birth control, intrauterine device, double barrier method or total abstinence;
Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Ospedale SS. Antonio e Biagio e Cesare Arrigo	Alessandria	AL	Italy	15121
2	Ematologia Azienda Ospedaliera Policlinico	Bari	BA	Italy
3	A.O. Spedali Civili	Brescia	BS	Italy	25100
4	A.O. Niguarda	Milano	MI	Italy	20162
5	Azienda Ospedaliera S. Gerardo Di Monza	Monza	Monza Brianza	Italy	20900
6	Osp. S. Maria delle Croci	Ravenna	RA	Italy	48121
7	A.O. Bianchi - Melacrino - Morelli	Reggio Calabria	RC	Italy	89125
8	Polo Pontino	Latina	Roma	Italy	04100
9	Ospedale di Matera	Matera		Italy	75100
10	Area Vasta Romagna e IRST	Meldola (FC)		Italy
11	Ospedali Riuniti Papardo	Messina		Italy	98158
12	Fondazione IRCCS Istituto Nazionale dei Tumori di Milano	Milano		Italy	120133
13	Ospedale S. Raffaele	Milano		Italy	20132
14	S.C.D.U Ematologia Azienda Ospedaliero Universitaria Maggiore	Novara		Italy
15	U.O. Complessa di Ematologia Ospedale di Parma	Parma		Italy	43100
16	IRCCS Policlinico S. Matteo di Pavia	Pavia		Italy	27100
17	Ausl Di Piacenza	Piacenza		Italy	29121
18	Azienda Ospedaliero Universitaria Pisana U.O. Ematologia	Pisa		Italy
19	AO Santa Maria Nuova	Reggio Emilia		Italy	42123
20	Ausl Di Rimini	Rimini		Italy	47924
21	Ematologia e Trapianto Istituto Regina Elena IFO	Roma		Italy
22	Policlinico Umberto I - Università "La Sapienza" - Istituto Ematologia -Dipartimento di Biotecnologie Cellulari ed Ematologia	Roma		Italy
23	Ospedale civile DH oncologico	Sassuolo (MO)		Italy
24	Policlinico Le Scotte Clinica Ematologica	Siena		Italy
25	SC Oncoematologia con autotrapianto AO Santa Maria	Terni		Italy	05100
26	A.O. Universitaria Citta' Della Salute E Della Scienza Di Torino	Torino		Italy	10126
27	A.O.U. Citta della Salute e della Scienza di Torino	Torino		Italy	10126